Forte Biosciences Stock Soars Following $2.2 Billion Acquisition by Argenx
Forte Biosciences saw its shares surge by 39.2% in pre-market trading following the announcement of a definitive agreement for its acquisition by Argenx, valued at approximately $2.2 billion. Under the terms of the all-cash deal, Argenx will pay $77 per share, which is about a 40% premium over Forte's last closing price. This offer also reflects an impressive 86% premium compared to Forte's volume-weighted average share price since the company disclosed positive results from its Phase 1b vitiligo trial on July 9, 2026.
The acquisition focuses on FB102, Forte's lead drug candidate, which is a first-in-class anti-CD122 antibody showing statistically significant results in treating vitiligo and celiac disease. This therapy aims to address autoimmune conditions that currently lack approved biologic treatments. Argenx stated that acquiring Forte will bolster its immunology pipeline by adding a promising clinical-stage asset with potential applications across various autoimmune diseases.
For Your Trading Desk
Sponsor Spike Success.
The transaction builds on Argenx's previous strategic investment in Forte and has received unanimous approval from the boards of directors of both companies. It is anticipated to close in the third quarter of 2026 and will be fully financed using Argenx's existing cash resources.
This announcement comes shortly after Barclays initiated coverage on Forte Biosciences, giving it an Overweight rating and a price target of $74, indicating growing confidence in the commercial prospects of FB102. The broader equity market has also been favorable, with the S&P 500 rising by 0.9%, the Dow Jones Industrial Average increasing by 0.8%, and the Nasdaq advancing by 1.4%, reflecting a positive investor sentiment.
Interest in biotechnology companies focused on autoimmune diseases remains strong, as larger pharmaceutical firms seek innovative assets to enhance their growth pipelines. With a fully financed cash offer of $77 per share, promising clinical data for FB102, and a supportive market environment, Forte Biosciences shares are trading just below the acquisition price, suggesting that investors are optimistic about the transaction's completion.




